In this episode, HBW Insight chats with Louise Witter, director and principal consultant at UK-based Chemical Legislation Professionals, about proposed revisions to the EU’s Classification, Labeling and Packaging Regulation (CLP) to introduce new hazard classes, including for endocrine disruptors. The discussion, just prior to the Commission’s adoption of the proposal on 19 December, ranges from implications for cosmetics companies to reflections on the EU Green Deal, which may be outpacing scientific consensus and endangering an already beleaguered and highly regulated chemicals industry.
Join thousands of industry professionals who rely on HBW Insight for daily insights
Already a subscriber?
“It’s quite likely [consumer wearable manufacturers] are changing the sensitivity and specificity based on consumer feedback, but not for medical reasons,” said Dipak Kotecha, a University of Birmingham professor of cardiology. Often, self-reported performance evidence from manufacturers is “low quality and biased.”
At a recent plenary session the European Parliament adopted a resolution calling on the European Commission to “conduct a new and comprehensive assessment” of the impact of the revised Urban Wastewater Treatment Directive on the pharmaceutical sector.
Germany’s Federal Institute for Risk Assessment says that there is "no evidence that people with androgenetic alopecia have special dietary needs or a special nutrient requirement.”
AESGP, MedTech Europe and other associations representing medtech companies including manufacturers of self-care devices call for such products to be included in European Commission proposals for “zero-for-zero” trade in industrial goods between Europe and the US.
AESGP, MedTech Europe and other associations representing medtech companies including manufacturers of self-care devices call for such products to be included in European Commission proposals for “zero-for-zero” trade in industrial goods between Europe and the US.
Just under half of Austrian pharmacists surveyed by Elpato Medien are “convinced that the OTC business will ensure the survival of their pharmacy.”
An application for melatonin as an OTC medicine is on the agenda for the next German switch committee meeting, despite the hormone being widely available in food supplements. Acyclovir as a buccal tablet and second-generation antihistamine rupatadine are also up for discussion.
